Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Capsaicin - Centrexion Therapeutics

Next Previous
Drug Profile

Capsaicin - Centrexion Therapeutics

Alternative Names: Adlea; ALGRX-4975; CNTX-4975; CNTX-4975-05; Trans-capsaicin - Centrexion Therapeutics; VLNX-4975

Latest Information Update: 02 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Anesiva
  • Developer Anesiva; Centrexion Therapeutics
  • Class Analgesics; Antipruritics; Catechols; Local anaesthetics; Monounsaturated fatty acids; Non-opioid analgesics; Polyunsaturated alkamides; Small molecules
  • Mechanism of Action GABA A receptor modulators; Melatonin receptor modulators; Substance P inhibitors; TRPV1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuropathic pain
  • New Molecular Entity No

Highest Development Phases

  • Phase III Pain
  • Discontinued Neuropathic pain; Postoperative pain

Most Recent Events

  • 29 May 2025 Discontinued - Phase-II for Neuropathic pain in USA (Intra-articular), before May 2025 (Centrexion Therapeutics pipeline, May 2025)
  • 10 Nov 2023 Pooled efficacy results from the phase III VICTORY-2 and VICTORY-1 trial were presented at the ACR Convergence 2023 (ACR-2023)
  • 10 Nov 2023 Efficacy and adverse events data from the phase III VICTORY-1 trial in Pain presented at the ACR Convergence 2023 (ACR-2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top